Zejula Maintenance Increases Time Without Symptoms or Toxicity in Recurrent OC Patients, Study Says

Zejula Maintenance Increases Time Without Symptoms or Toxicity in Recurrent OC Patients, Study Says
Taking Zejula (niraparib) as a maintenance therapy may increase time without symptoms or toxicities from treatment in women with recurrent ovarian cancer, a new study found. These results suggest that Zejula could increase quality of life in addition to slowing cancer growth. The study, "Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial," was published in the Journal of Clinical Oncology. Zejula, by the GSK company Tesaro, is a PARP inhibitor that works by interfering with cancer cells' ability to repair their DNA, thereby causing their death. It is a once-daily, oral medicine indicated for maintenance treatment for women with recurrent ovarian cancer who have had a response — complete or partial — to platinum-based chemotherapy. Its approval by the U.S. Food and Drug Administration in March 2017 was based on data from a Phase 3 clinical trial called ENGOT-OV16/NOVA (NCT01847274). That trial enr
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *